Stem Cell & Regenerative Medicine Training for Physicians

Autologous conditioned plasma (ACP) is a form of platelet-rich plasma prepared using a specialized double-syringe system that produces a concentrated preparation of the patient's own growth factors with minimal red and white blood cell contamination. ACP offers a more refined platelet concentrate compared to standard PRP methods, potentially reducing inflammatory response at the injection site while delivering targeted regenerative growth factors to damaged tissue.

The course covers autologous conditioned plasma (ACP), platelet-rich plasma (PRP) therapy, bone marrow aspirate concentrate (BMAC), and amniotic tissue-derived products. You will learn the science behind each regenerative modality, the preparation and processing protocols, and the clinical injection techniques for applying these therapies to musculoskeletal pain conditions, degenerative joint disease, and soft tissue injuries.

ACP and biologic therapies are used to treat osteoarthritis of the knee, hip, shoulder, and other joints; chronic tendinopathy including rotator cuff, Achilles, and patellar tendon conditions; ligament sprains and partial tears; muscle injuries; plantar fasciitis; and various other musculoskeletal conditions where tissue repair and regeneration are the treatment goal. The course covers patient selection criteria for each condition.

Currently, most regenerative medicine treatments including ACP, PRP, and BMAC therapies are considered elective and are not covered by standard insurance plans, though this is evolving as clinical evidence grows. Patients typically pay out of pocket, which means regenerative services command premium fees — often $1,500 to $5,000 or more per treatment — with no insurance billing overhead. This makes ACP and biologics among the highest-margin services a practice can offer.

The course provides thorough education on FDA regulatory frameworks for regenerative medicine products. Autologous ACP, PRP, and bone marrow concentrate prepared at the point of care are generally considered minimally manipulated and fall within current FDA regulatory guidelines. The course covers the specific regulatory distinctions between different regenerative products and how to maintain compliance in your clinical practice.

Regenerative medicine services are among the highest-revenue procedural offerings in outpatient pain management. Individual ACP and PRP treatments typically command $500 to $1,500, while BMAC treatments often range from $3,000 to $8,000 or more per treatment area. Practices that establish robust regenerative medicine programs commonly generate $20,000 to $50,000+ per month in additional revenue from these services.

No, bone marrow aspiration is just one component of regenerative medicine. ACP and PRP therapy, which require only a simple blood draw and centrifugation, are the most accessible entry points into regenerative pain management. The course teaches both BMAC and ACP/PRP so you can choose the regenerative approaches that best fit your practice scope, comfort level, and patient population.

The essential equipment includes a centrifuge system for ACP and PRP preparation, blood draw supplies, and appropriate injection supplies. For bone marrow aspirate concentrate, you will additionally need bone marrow aspiration kits and a specialized centrifuge capable of BMAC processing. The course provides detailed equipment guidance and vendor recommendations to help you set up your regenerative pain management program efficiently.

Regenerative medicine integrates naturally into primary care, pain management, orthopedic, and sports medicine practices. Your existing patient base with osteoarthritis, tendinopathy, and chronic musculoskeletal conditions represents an immediate market for regenerative services. Many physicians start with PRP (simpler, lower investment) and expand to BMAC/stem cell procedures as their practice grows. The cash-pay model operates alongside your existing insurance-based services.

The course provides comprehensive FDA regulatory education. Autologous PRP and bone marrow concentrate prepared at the point of care are generally considered minimally manipulated and fall within current FDA guidelines. The course covers the specific regulatory distinctions, documentation requirements, and marketing compliance rules that ensure your regenerative practice operates within the regulatory framework.

Practices with established regenerative medicine programs typically generate $20,000 to $50,000+ per month. Individual PRP treatments command $500 to $1,500, and BMAC/stem cell procedures generate $3,000 to $8,000+ per treatment area. The cash-pay model means 100% of revenue flows directly to the practice with no insurance adjustments, claims processing, or reimbursement delays.

While physicians have the legal authority to perform many procedures, hands-on training under expert supervision dramatically accelerates the learning curve, reduces complication risk, and provides the clinical confidence needed to deliver exceptional patient outcomes from day one. Empire's structured curriculum, live patient practice, and CME accreditation also satisfy credentialing and malpractice insurance requirements that self-study alone cannot fulfill.

Adding procedural services creates new revenue streams that can significantly increase your practice income — aesthetic services alone can add $200K-$500K+ in annual revenue. Beyond finances, offering in-demand procedures improves patient retention, attracts new patient demographics, and positions your practice competitively in a market where patients increasingly expect comprehensive service offerings from their healthcare providers.

Yes. All Empire Medical Training courses for physicians are accredited through the Accreditation Council for Continuing Medical Education (ACCME) and provide AMA PRA Category 1 Credit™. These credits satisfy continuing medical education requirements for state license renewal and specialty board Maintenance of Certification (MOC) programs.